Pfizer Inc
Healthy Returns: What to expect from pharma at the JPM conference
Heidi Overton, Novo Nordisk CEO Maziar Mike Doustdar, Eli Lilly CEO David A. Ricks, and U.S. Secretary of Commerce Howard Lutnick listen while U.S. President Donald Trump announces a deal with Eli Lilly and Novo Nordisk on to reduce the prices of GLP-1 weight‑loss drugs during an event in the Oval Office at the White […]
Read More
Big Pharma race to snap up biotech assets as $170 billion patent cliff looms
Two employees in pharmaceutical industry wearing protective gloves, mask, cap and white suit seen standing by the machine that is the part of the medicaments production during the working hours in a pharmaceutical manufacturing. Extreme-photographer | E+ | Getty Images A multitude of factors are coming together to bring a big burst in biotech M&A. […]
Read More
Novo Nordisk enters 2026 on the defense as it faces a ‘must-win’ battle in the U.S. market
Still life of the big three injectable prescription weight loss medicines. Ozempic, Victoza and Wegovy. (Photo by: Michael Siluk/UCG/Universal Images Group via Getty Images) Ucg | Universal Images Group | Getty Images Novo Nordisk’s shift from a market darling to a serious underperformer has set the stage for a transitional 2026 as the Danish drugmaker […]
Read More
Nine of the largest pharma companies ink deals with Trump to lower drug prices
President Donald Trump signs an executive order aimed at reducing the cost of prescription drugs and pharmaceuticals by 30% to 80% during an event in the Roosevelt Room of the White House on May 12, 2025, in Washington, DC. Andrew Harnik | Getty Images Several of the largest U.S. and European-based drugmakers inked deals with […]
Read More
Wall Street banked on a flurry of deals under Trump in 2025. It wasn’t that simple
The Wall Street Bull statue covered in snow on Nov. 15, 2018. Erik Mcgregor | Lightrocket | Getty Images Wall Street expected U.S. mergers and acquisitions to roar back in 2025. The reality was something closer to fits and starts. Following the re-election of President Donald Trump more than a year ago, executives and bankers […]
Read More
Pfizer’s modest 2026 outlook shows its big investments will take time to pay off
Smith Collection | Archive Photos | Getty Images Pfizer on Tuesday forecast modest 2026 guidance as it looks to longer-term investments in its pipeline to counter waning Covid product sales and declines from older drugs. Those hurdles aren’t surprising or new for Pfizer, which has seen a dramatic decline in Covid vaccine and antiviral sales […]
Read More
Stocks making the biggest moves premarket: Pfizer, Roku, Kraft Heinz & more
Check out the companies making headlines before the bell: Pfizer — The pharma giant issued disappointing 2026 earnings guidance. Pfizer a profit between $2.80 per share and $3 per share for the coming year. Analysts polled by LSEG expected earnings per share of $3.05 for 2026. The company also reaffirmed its 2025 outlook. Shares hovered […]
Read More
Healthy Returns: FDA may add its strongest safety warning to Covid vaccines. Here’s what to know
A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. The Food and Drug Administration may add its strongest safety warning to Covid shots – marking another major shift in vaccine oversight. It could also expand a […]
Read More
Danish weight loss drug maker outlines ambitious 2030 strategy, ramping up pressure on Novo, Lilly
Celsopupo | Istock | Getty Images Zealand Pharma on Thursday outlined an ambitious five-year strategy for its anti-obesity portfolio Thursday, spotlighting how growing competition from smaller players is tightening the race for market leaders Novo Nordisk and Eli Lilly as more of these medicines near market entry. The new strategy, “Metabolic Frontier 2030,” comes as Zealand […]
Read More
The Fed meeting, pressure on Oracle, Target’s fashion-forward renovation and more in Morning Squawk
Television stations broadcast Jerome Powell, chairman of the US Federal Reserve, speaking after a Federal Open Market Committee (FOMC) meeting on the floor of the New York Stock Exchange in New York, US, on Wednesday, Oct. 29, 2025. Michael Nagle | Bloomberg | Getty Images This is CNBC’s Morning Squawk newsletter. Subscribe here to receive future editions […]
Read More